Drospirenone-containing contraception: curative and preventive aspects of use

Abstract

The use of combined hormonal contraceptives is a pathogenetically sound method of treating pathological conditions associated with the menstrual cycle. The study, the purpose of which was to study the effectiveness and acceptability of hormonal microdosed combined oral contraceptive containing 20 mcg ethinylestradiol and 3 mg drospirenone (Yaz®, Bayer HealthCare Pharmaceuticals, Germany), in the treatment of women who suffer from premenstrual syndrome manifestations and of moderate to severe dysmenorrhea. As a result of treatment revealed a statistically significant reduction of the symptoms of premenstrual syndrome, in the absence of serious adverse effects.The study showed high efficacy and acceptability of a microdosed drospirenone-containing combined oral contraceptive in 24/4 mode for the treatmentof women with premenstrual syndrome secondary to severe.

Keywords

• hormonal contraception
• drospirenone
• folic acid
• pregnancy